301015 百洋医药
已收盘 07-31 15:00:00
资讯
新帖
简况
百洋医药（301015）股东百洋医药集团有限公司质押2456万股，占总股本4.67%
证券之星 · 07-29 10:22
百洋医药（301015）股东百洋医药集团有限公司质押2456万股，占总股本4.67%
百洋医药(301015.SZ)控股股东拟减持不超3%股份
智通财经网 · 07-21
百洋医药(301015.SZ)控股股东拟减持不超3%股份
百洋医药（301015）股东百洋医药集团有限公司质押560万股，占总股本1.07%
证券之星 · 07-17
百洋医药（301015）股东百洋医药集团有限公司质押560万股，占总股本1.07%
百洋医药：高端医疗器械创新发展获政策支持
证券之星 · 07-04
百洋医药：高端医疗器械创新发展获政策支持
7月3日百洋医药涨7.50%，惠升医药健康6个月持有期混合基金重仓该股
证券之星 · 07-03
7月3日百洋医药涨7.50%，惠升医药健康6个月持有期混合基金重仓该股
百洋医药：ZAP-X火星舟放射外科机器人已在中国获批上市
证券之星 · 06-27
百洋医药：ZAP-X火星舟放射外科机器人已在中国获批上市
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液临床III期试验结果已达主要终点和次要终点
证券之星 · 06-27
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液临床III期试验结果已达主要终点和次要终点
百洋医药：公司的控股股东有投资全球首创的骨坏死药物公司
证券之星 · 06-19
百洋医药：公司的控股股东有投资全球首创的骨坏死药物公司
百洋医药：公司及控股子公司无逾期担保情况
证券日报网 · 06-16
百洋医药：公司及控股子公司无逾期担保情况
百洋医药新提交2件商标注册申请
证券之星 · 06-14
百洋医药新提交2件商标注册申请
百洋医药：公司为ZAP-X火星舟放射外科机器人在国内的独家经销商
证券之星 · 06-13
百洋医药：公司为ZAP-X火星舟放射外科机器人在国内的独家经销商
百洋医药：公司运营的锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液是我国第一个自主研发的核医学1类新药
证券之星 · 06-13
百洋医药：公司运营的锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液是我国第一个自主研发的核医学1类新药
百洋医药：扶正化瘀片是国家医保和基药品种在抗肝纤维化领域占据领先地位
证券之星 · 06-13
百洋医药：扶正化瘀片是国家医保和基药品种在抗肝纤维化领域占据领先地位
百洋医药涨8.98%，开源证券一个月前给出“买入”评级
证券之星 · 06-10
百洋医药涨8.98%，开源证券一个月前给出“买入”评级
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液正全力推进重新提交审核
证券之星 · 06-06
百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液正全力推进重新提交审核
每周股票复盘：百洋医药（301015）分红及转股价格调整
证券之星 · 05-24
每周股票复盘：百洋医药（301015）分红及转股价格调整
百洋医药：公司已未代理紫杉醇
证券之星 · 05-07
百洋医药：公司已未代理紫杉醇
百洋医药：公司股东已终止减持
证券之星 · 04-29
百洋医药：公司股东已终止减持
百洋医药：公司严格按照会计政策计提存货跌价准备
证券之星 · 04-29
百洋医药：公司严格按照会计政策计提存货跌价准备
百洋医药：北京凯斯利康为公司集团投资孵化的技术平台
证券之星 · 04-29
百洋医药：北京凯斯利康为公司集团投资孵化的技术平台
加载更多
公司概况
公司名称：
青岛百洋医药股份有限公司
所属行业：
批发业
上市日期：
2021-06-30
主营业务：
青岛百洋医药股份有限公司的主营业务是为医药产品生产企业提供商业化整体解决方案。公司的主要产品是药品、医疗器械、其他产品、品牌服务、其他服务。
发行价格：
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":22.07,"timestamp":1753945389000,"preClose":21.92,"halted":0,"volume":12315964,"delay":0,"changeRate":0.0068,"floatShares":526000000,"shares":526000000,"eps":1.1617,"marketStatus":"已收盘","change":0.15,"latestTime":"07-31 15:00:00","open":21.94,"high":22.45,"low":21.66,"amount":271000000,"amplitude":0.036,"askPrice":22.09,"askSize":55,"bidPrice":22.07,"bidSize":77,"shortable":0,"etf":0,"ttmEps":1.1617,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1754011800000},"marketStatusCode":5,"adr":0,"adjPreClose":21.92,"symbolType":"stock","openAndCloseTimeList":[[1753925400000,1753932600000],[1753938000000,1753945200000]],"highLimit":24.11,"lowLimit":19.73,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525619476,"isCdr":false,"pbRate":4.88,"roa":"--","peRate":18.99802,"roe":"3.67%","epsLYR":1.32,"committee":-0.267544,"marketValue":11600000000,"turnoverRate":0.0234,"status":0,"floatMarketCap":11599000000},"requestUrl":"/m/hq/s/301015","defaultTab":"news","newsList":[{"id":"2555037547","title":"百洋医药（301015）股东百洋医药集团有限公司质押2456万股，占总股本4.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555037547","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555037547?lang=zh_cn&edition=full","pubTime":"2025-07-29 18:22","pubTimestamp":1753784550,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药7月29日公开信息显示，股东百洋医药集团有限公司向青岛银行股份有限公司市北第二支行合计质押2456.0万股，占总股本4.67%。百洋医药主营业务：为医药产品生产企业提供商业化整体解决方案,涵盖品牌运营、批发配送及零售三个板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900032445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2553747761","title":"百洋医药(301015.SZ)控股股东拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2553747761","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553747761?lang=zh_cn&edition=full","pubTime":"2025-07-21 21:40","pubTimestamp":1753105201,"startTime":"0","endTime":"0","summary":"百洋医药(301015.SZ)发布公告，控股股东百洋医药集团有限公司计划在本公告披...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/3.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2552488219","title":"百洋医药（301015）股东百洋医药集团有限公司质押560万股，占总股本1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552488219","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552488219?lang=zh_cn&edition=full","pubTime":"2025-07-17 18:18","pubTimestamp":1752747507,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药7月17日公开信息显示，股东百洋医药集团有限公司向兴业国际信托有限公司合计质押560.0万股，占总股本1.07%。百洋医药主营业务：为医药产品生产企业提供商业化整体解决方案,涵盖品牌运营、批发配送及零售三个板块。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071700030371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2548365117","title":"百洋医药：高端医疗器械创新发展获政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2548365117","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548365117?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:24","pubTimestamp":1751617448,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药07月04日在投资者关系平台上答复投资者关心的问题。请问对于公司具体有哪些影响？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400025498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","BK1222","159883","301015","BK0250","09996","09997","BK1583","BK1574"],"gpt_icon":0},{"id":"2548987962","title":"7月3日百洋医药涨7.50%，惠升医药健康6个月持有期混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548987962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548987962?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:30","pubTimestamp":1751531408,"startTime":"0","endTime":"0","summary":"证券之星消息，7月3日百洋医药涨7.50%，收盘报21.51元，换手率4.47%，成交量23.48万手，成交额4.99亿元。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为惠升基金的惠升医药健康6个月持有期混合。惠升医药健康6个月持有期混合目前规模为5.78亿元，最新净值0.6523，较上一交易日下跌0.65%，近一年下跌1.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300026213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2546976847","title":"百洋医药：ZAP-X火星舟放射外科机器人已在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2546976847","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546976847?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:09","pubTimestamp":1751011762,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)06月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的黑科技zap—x医疗机器人运营到底到了哪一步？是否通过了医疗器械的各种审核？是否已经可以开始运营了？百洋医药回复：投资者您好，ZAP-X火星舟放射外科机器人已于2023年6月正式在中国获批上市，目前公司正按经营计划有序推进其商业化，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062700024941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2546632797","title":"百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液临床III期试验结果已达主要终点和次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2546632797","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546632797?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:09","pubTimestamp":1751011756,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药06月27日在投资者关系平台上答复投资者关心的问题。公司作为火星舟外科机器人的独家经销商，目前在医学相关的领域获得哪些核心竞争力或者专利百洋医药回复：投资者您好，公司运营的“锝99mTc肼基烟酰胺聚乙二醇双环RGD肽注射液”临床III期试验结果已达主要终点和次要终点；ZAP-X火星舟放射外科机器人是一款专为颅内和头颈部肿瘤、病变研发的放射外科系统，该套设备已于2023年6月正式在中国获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062700024933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2544159540","title":"百洋医药：公司的控股股东有投资全球首创的骨坏死药物公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2544159540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544159540?lang=zh_cn&edition=full","pubTime":"2025-06-19 16:39","pubTimestamp":1750322350,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)06月19日在投资者关系平台上答复投资者关心的问题。投资者提问：据说公司布局了一款创新药是全球首创骨坏死药物！请问是否属实？进展如何了？百洋医药回复：尊敬的投资者您好，公司的控股股东有投资全球首创的骨坏死药物公司，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061900023433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2543672922","title":"百洋医药：公司及控股子公司无逾期担保情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2543672922","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543672922?lang=zh_cn&edition=full","pubTime":"2025-06-16 19:41","pubTimestamp":1750074060,"startTime":"0","endTime":"0","summary":"证券日报网讯6月16日晚间，百洋医药发布公告称，公司及公司控股子公司不存在对合并报表外单位提供担保的情况。公司及控股子公司无逾期担保情况，无涉及诉讼的担保事项，不存在因担保被判决败诉而应承担损失的情形。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-06-16/doc-infahqyc7437560.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-06-16/doc-infahqyc7437560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2543983806","title":"百洋医药新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2543983806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543983806?lang=zh_cn&edition=full","pubTime":"2025-06-15 04:55","pubTimestamp":1749934520,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日青岛百洋医药股份有限公司新提交2件商标注册申请。商标申请详情如下：今年以来青岛百洋医药股份有限公司新申请注册商标46件，截止目前公司共持有注册商标437件，另有154件商标尚在注册申请中。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061500000347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2543058495","title":"百洋医药：公司为ZAP-X火星舟放射外科机器人在国内的独家经销商","url":"https://stock-news.laohu8.com/highlight/detail?id=2543058495","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543058495?lang=zh_cn&edition=full","pubTime":"2025-06-13 16:00","pubTimestamp":1749801652,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药06月13日在投资者关系平台上答复投资者关心的问题。投资者提问：ZAP-X 官方公众号2025年1月24日文章披露：平台即将与一家位于中国北京、世界领先的三级甲等精神病学专科医院，以及北京脑安医疗科技共同发起一项协作研究计划，并很快启动人体临床试验。标志着探索利用放射神经调控治疗抑郁症道路上迈出了重要一步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061300021002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2543505841","title":"百洋医药：公司运营的锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液是我国第一个自主研发的核医学1类新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2543505841","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543505841?lang=zh_cn&edition=full","pubTime":"2025-06-13 16:00","pubTimestamp":1749801640,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药06月13日在投资者关系平台上答复投资者关心的问题。百洋医药回复：投资者您好，公司运营的锝99mTc肼基烟酰胺聚乙二醇双环RGD肽注射液是以整合素为靶点的放射性药物，是我国第一个自主研发的核医学1类新药、全球首个用于SPECT显像的广谱肿瘤显像剂，解决了SPECT影像技术用于肿瘤显像诊断、分期和疗效监测的瓶颈问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061300020981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2543550379","title":"百洋医药：扶正化瘀片是国家医保和基药品种在抗肝纤维化领域占据领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2543550379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543550379?lang=zh_cn&edition=full","pubTime":"2025-06-13 15:57","pubTimestamp":1749801452,"startTime":"0","endTime":"0","summary":"投资者提问：最近看到一篇报道，公司的扶正化瘀片2013年在美国二期临床试验结果其疗效低于安慰剂组是否属实？希望公司公布该药在国内的试验报告，患者有知情权。谢谢百洋医药回复：投资者您好，扶正化瘀片（胶囊）是国家医保和基药品种，也是唯一获得FDA批准的在美国完成Ⅱ期临床的肝病领域中成药，在抗肝纤维化领域占据领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061300020554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2542960123","title":"百洋医药涨8.98%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2542960123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542960123?lang=zh_cn&edition=full","pubTime":"2025-06-10 16:29","pubTimestamp":1749544152,"startTime":"0","endTime":"0","summary":"今日百洋医药涨8.98%，收盘报21.11元。2025年4月25日，开源证券研究员余汝意,巢舒然发布了对百洋医药的研报《公司信息更新报告：经营业绩相对承压，自有品牌为下一阶段发展重点》，该研报对百洋医药给出“买入”评级。研报中预计2025-2027年归母净利润分别为7.56/9.15/11.30亿元，EPS为1.44/1.74/2.15元/股，当前股价对应PE为12.6/10.4/8.4倍，我们看好公司核心品牌运营业务的长期成长潜力及管线布局，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061000024554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","161027"],"gpt_icon":0},{"id":"2541883670","title":"百洋医药：锝[99mTc]肼基烟酰胺聚乙二醇双环RGD肽注射液正全力推进重新提交审核","url":"https://stock-news.laohu8.com/highlight/detail?id=2541883670","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541883670?lang=zh_cn&edition=full","pubTime":"2025-06-06 09:57","pubTimestamp":1749175033,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，“锝99mTc肼基烟酰胺聚乙二醇双环RGD肽注射液”，截止今天都没提交审核，这个有没有一个大概的时间点？又一个月快过去了。。。百洋医药回复：尊敬的投资者您好，锝99mTc肼基烟酰胺聚乙二醇双环RGD肽注射液”正全力推进重新提交审核，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060600007732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2537164415","title":"每周股票复盘：百洋医药（301015）分红及转股价格调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2537164415","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537164415?lang=zh_cn&edition=full","pubTime":"2025-05-24 12:55","pubTimestamp":1748062510,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘，百洋医药报收于18.35元，较上周的18.34元上涨0.05%。本周，百洋医药5月21日盘中最高价报19.17元。百洋医药当前最新总市值96.45亿元，在医药商业板块市值排名11/31，在两市A股市值排名1601/5148。此外，公司还发布了关于百洋转债恢复转股的公告，百洋转债将于2025年5月27日起恢复转股，此前因实施2024年度权益分派，百洋转债自2025年5月16日至2025年5月26日期间暂停转股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400012047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2533627993","title":"百洋医药：公司已未代理紫杉醇","url":"https://stock-news.laohu8.com/highlight/detail?id=2533627993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533627993?lang=zh_cn&edition=full","pubTime":"2025-05-07 15:30","pubTimestamp":1746603055,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：关于紫杉酮相关的传言比较多，所以想请教几个问题：1.公司和谊众合作推广紫杉酮，还在继续吗？2.紫杉酮跌价计提，据说是因为紫杉酮进入医保后，大幅降低了价格？百洋医药回复：尊敬的投资者您好，公司已未代理紫杉醇，公司严格按照会计准则计提减值，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700018201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2531635739","title":"百洋医药：公司股东已终止减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2531635739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531635739?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:54","pubTimestamp":1745931259,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价从去年就开始大幅度下跌！在别的企业都来稳定股价坚定看好的时候，贵司大股东却依然决定低位减持导致股价继续大跌！在这之后公司又出现业绩严重下滑的情况导致股价再次暴跌！请问面对如此局面大股东还要减持吗？是否考虑延缓减持并开始提升市值计划？百洋医药回复：投资者您好，公司股东已终止减持，我们会将您的建议反馈给公司管理层，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900040251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2531220036","title":"百洋医药：公司严格按照会计政策计提存货跌价准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2531220036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531220036?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:48","pubTimestamp":1745912905,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司早已取消了紫杉醇胶束的合作，怎么还会有计提跌价？百洋医药回复：投资者您好，公司严格按照会计政策计提存货跌价准备，感谢您的关注与支持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900025433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2531220716","title":"百洋医药：北京凯斯利康为公司集团投资孵化的技术平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2531220716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531220716?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:45","pubTimestamp":1745912719,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：当地时间4月10日，美国食品药品监督管理局宣称，计划通过更有效、与人类相关的方法，取代单克隆抗体疗法和其他药物开发中的动物实验，该举措旨在提高药物安全性，加快评估过程，同时减少动物实验，降低研发成本，最终降低药品价格。百洋医药投资的北京凯斯利康科技，作为多器官芯片微生理系统研发平台，是否收益？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900024999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753950462023,"stockEarnings":[{"period":"1week","weight":0.0092},{"period":"1month","weight":0.0927},{"period":"3month","weight":0.295},{"period":"6month","weight":-0.0181},{"period":"1year","weight":0.0622},{"period":"ytd","weight":-0.0554}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0497},{"period":"3month","weight":0.1027},{"period":"6month","weight":0.1123},{"period":"1year","weight":0.2558},{"period":"ytd","weight":0.0788}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"16364人(较上一季度增加45.68%)","perCapita":"32116股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52561万元","survey":" 青岛百洋医药股份有限公司的主营业务是为医药产品生产企业提供商业化整体解决方案。公司的主要产品是药品、医疗器械、其他产品、品牌服务、其他服务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}